IP Library › Granted Patent US 10,030,017
Granted Patent B2
US 10,030,017 · App. 15/071,050 · Granted Jul 24, 2018

Histone demethylase inhibitors

Inventors: Amogh Boloor (San Diego, CA); Toufike Kanouni (La Jolla, CA); Jeffrey Alan Stafford (San Diego, CA); James Marvin Veal (Apex, NC); Michael Brennan Wallace (San Diego, CA)
Assignee: Celgene Quanticel Research, Inc.
C07D471/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,030,017
App. No.
15/071,050
Granted
Jul 24, 2018
Kind
B2
Abstract

The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyrido[3,4-d]pyrimidin-4-one derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer, melanoma, and the like.

Claims (11)

1. A substituted pyrido[3,4-d]pyrimidin-4-one derivative compound having the structure of Formula (IIIa),

or pharmaceutically acceptable salt thereof, wherein,

X is C 1 -C 3 alkyl and n is 0 or 1;

Y is C 1 -C 3 alkyl;

Z is C 1 -C 4 alkyl, and m is 0, 1, or 2,

wherein an effective amount of said substituted pyrido[3,4-d]pyrimidin-4-one derivative compound inhibits histone demethylase activity.

2. A pharmaceutical composition comprising a compound of claim 1 .

3. The compound, or pharmaceutically acceptable salt thereof, of claim 1 , selected from the group consisting of:

2-[4-(4-tert-butyl-N-methylanilino)phenoxy]pyrido[3,4-d]pyrimidin-4-ol;

and 2-(4-((4-isopropylphenyl)(methyl)amino)-3-methylphenoxy)pyrido[3,4-d]pyrimidin-4-ol.

4. A pharmaceutical composition comprising a compound of claim 3 .

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 21, 2016
From: BOLOOR, AMOGH; KANOUNI, TOUFIKE; STAFFORD, JEFFREY ALAN; VEAL, JAMES MARVIN; WALLACE, MICHAEL BRENNAN
To: CELGENE QUANTICEL RESEARCH, INC.
Reel/Frame 038346/0413 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 8, 2016
From: QUANTICEL PHARMACEUTICALS, INC.
To: CELGENE QUANTICEL RESEARCH, INC.
Reel/Frame 038399/0685 →
Continuity (3)
Continuation In Part 14855950 · Sep 16, 2015
Provisional Application 62051691 · Sep 17, 2014
Related Publication 20160194323A1 · Jul 7, 2016